ROBOTIC CANCER SURGERY:
WORLD-CLASS EXPERTISE IN CHINA

Minimally invasive surgery encompasses all approaches that achieve the same oncological operation — tumour resection, lymph node dissection, reconstruction — through smaller incisions or natural body openings, reducing physical trauma without compromising cancer control.

“The oncological goal is always identical: same margins, same lymphadenectomy, same completeness of resection — achieved through smaller access.”

• Conventional Laparoscopy

  Multiple 5–12mm incisions, camera and straight instruments, HD monitor view. The gold standard for many cancer operations with the largest evidence base. Available at far more hospitals than robotic platforms.

• Robotic-Assisted Surgery (da Vinci)

  3D magnified vision, fully wristed EndoWrist instruments with 7 degrees of freedom, motion scaling, and tremor elimination. Optimised for confined anatomical spaces requiring fine dissection and precise suturing.

• VATS (Video-Assisted Thoracoscopic Surgery)

  Minimally invasive approach to the chest through small intercostal incisions. Standard of care for Stage I–II lung cancer lobectomy; fewer pulmonary complications and shorter stay vs thoracotomy.

• Single-Port & Natural Orifice (NOTES)

  All instruments through one 25mm port (da Vinci SP) or through natural body openings — no external incision. The frontier of scar-free oncological surgery; TORS for head and neck cancer is the most established application.

Robotic surgery addresses the core limitations of conventional laparoscopy — 2D vision, no wrist articulation, tremor transmission — that make complex operations in confined spaces more difficult.

Advantages are documented across randomised trials, meta-analyses, and large registry studies for laparoscopic and robotic approaches versus open surgery.

• 1–3 daysShorter Hospital StayConsistently demonstrated across prostatectomy, colectomy, hysterectomy, and nephrectomy trials.
• 60–80%Less Blood LossRobotic prostatectomy averages 150–200ml vs 500–1,000ml with open surgery; lower transfusion rates.
• EquivalentOncological OutcomesR0 resection rates, lymph node yield, disease-free and overall survival equivalent to open surgery in major RCTs.

Applicability of MIS varies by cancer type. It is most strongly established where anatomy suits an endoscopic approach and where robust randomised trial evidence supports it.

These are the most clinically established robotic cancer operations, with the strongest evidence base and the highest surgical volumes globally — including at leading Chinese centres.

• Robotic Radical Prostatectomy (RARP)

  Dominant approach for localised prostate cancer at high-volume centres worldwide. Estimated blood loss 150–200ml vs 500–1,000ml open. Median hospital stay 1–2 days. Advantages in nerve-sparing precision and urethrovesical anastomosis quality translate to better continence and potency recovery in experienced hands.

• Robotic TME for Rectal Cancer

  Total mesorectal excision in the narrow male pelvis is the most technically demanding standard colorectal operation. Robotic instruments' articulation and 3D vision improve dissection in the precise anatomical plane, reduce conversion rates (ROLARR trial), and may improve autonomic nerve preservation — reducing bladder and sexual dysfunction rates.

• Robotic Partial Nephrectomy

  Preferred over laparoscopic partial nephrectomy at experienced centres for renal tumours requiring nephron-sparing. Robotic articulation reduces warm ischaemia time during reconstruction, reduces conversion to radical nephrectomy, and enables excision of more complex tumours.

• Transoral Robotic Surgery (TORS) — Head & Neck

  da Vinci SP system accesses the oropharynx through the open mouth — no external incision. Established for HPV-positive tonsil and base-of-tongue cancers as an alternative to chemoradiation, avoiding long-term xerostomia and dysphagia. Central to de-escalation strategies in HPV-positive oropharyngeal cancer.

• Robotic Gastrectomy for Gastric Cancer

  Chinese and Korean centres have performed more laparoscopic and robotic D2 gastrectomies than almost any other surgical community globally. Multiple Asian RCTs (CLASS-01, KLASS-01) confirm equivalent oncological outcomes to open D2 gastrectomy. China is the single most experienced destination globally for minimally invasive gastric cancer surgery.

MIS is not universally superior. The goal is always the best oncological operation for that patient — not the minimally invasive approach for its own sake.

Of all factors influencing cancer surgery outcomes, surgeon and hospital volume is the most consistently documented. Higher volume = lower complication rates, lower conversion rates, better margins, better survival.

“A surgeon who performs 200 robotic prostatectomies per year is a genuinely different technical proposition from one who performs 20.”

• Ask your surgeon: annual personal volume

  How many of this specific operation — robotic prostatectomy, laparoscopic colectomy, robotic gastrectomy — do you personally perform per year? This is standard information every experienced cancer surgeon should provide.

• Ask: positive surgical margin rate

  R0 (clear margin) resection rate is the single most important surgical quality metric. High-volume surgeons have published or trackable margin rates. Ask for theirs.

• Ask: personal conversion-to-open rate

  Conversion to open surgery is not a failure, but a low rate at high volume reflects proficiency. A surgeon with a 15% conversion rate vs a 2% rate at the same volume are different propositions.

• Understand the learning curve

  Robotic prostatectomy requires 100–250 cases before plateau outcomes. Robotic rectal surgery: 30–70 cases. Robotic Whipple or oesophagectomy: 80–100+ cases. Seek surgeons past their learning curve for complex operations.

Recovery is substantially faster than open surgery but still requires careful planning — especially for international patients who need to remain in-country for follow-up before flying home.

China has the world's largest installed base of da Vinci robotic systems outside the USA. Surgeons at leading centres have accumulated some of the highest global volumes for robotic gastrectomy, colorectal, prostatectomy, liver, and thyroid surgery.

• Gastric Cancer Surgery

  China has the world's second-highest gastric cancer burden. Chinese multicentre RCTs (CLASS-01, CLASS-02) have provided definitive evidence for laparoscopic gastrectomy. No other country offers comparable volumes of minimally invasive D2 gastrectomy for international patients.

• Hepatobiliary Surgery

  Zhongshan Hospital (Fudan) and other Chinese liver centres have the world's most extensive laparoscopic liver resection experience, including major hepatectomy, driven by China's high HCC burden. Chinese hepatobiliary surgeons are technically among the most experienced globally.

• Scar-Free Thyroid Surgery

  China has been a global pioneer of transoral endoscopic thyroidectomy (TOETVA) and robotic transoral thyroid surgery. Multiple Chinese centres have the highest global volumes of scar-free thyroid approaches — particularly relevant for young Asian women prioritising neck cosmesis.

• Domestic Robotic Platforms

  China is developing its own robotic surgery platforms — Toumai (MicroHand S), KangDuo — with NMPA approval. These systems are being deployed across Chinese cancer centres, reducing dependence on imported equipment and enabling broader robotic access at lower procedure cost.

Chinese cancer centres offer robotic surgery at 60–80% lower cost than equivalent procedures at US academic medical centres, with equivalent technology and high-volume surgical expertise.

CancerFax provides end-to-end navigation from medical record review to post-surgical follow-up handover — removing the logistical, linguistic, and medical complexity of accessing surgery abroad.

1. 1

   Upload Imaging and Medical Reports

   Submit your CT/MRI, pathology, staging workup, and prior treatment records. CancerFax compiles and translates all materials into a case summary for Chinese oncology specialist review.

2. 2

   Surgical Assessment and MIS Suitability Review

   CancerFax reviews whether your tumour is appropriate for a minimally invasive approach — size, stage, anatomy, prior surgery — and identifies the optimal procedure and approach.

3. 3

   Surgeon and Centre Matching

   Based on tumour type, required procedure, and surgeon volume data, CancerFax identifies the most appropriate Chinese surgical oncologist and hospital — prioritising surgeons past their learning curve with published outcomes.

4. 4

   Remote Surgical Consultation

   Before committing to travel, CancerFax facilitates a remote consultation with the proposed surgeon — reviewing imaging, confirming the surgical plan, and answering patient questions.

5. 5

   In-Country Surgical Admission and Support

   CancerFax arranges hospital admission, interpreter services, accommodation, and daily liaison during the surgical stay and post-operative recovery period in China.

6. 6

   Post-Surgical Handover and Telemedicine Follow-Up

   On return home, CancerFax facilitates translated surgical and pathology record transfer to the home oncologist and telemedicine follow-up with the Chinese surgical team.

Frequently Asked Questions